ClinicalTrials.gg
CompletedNCT01256554Updated Oct 25, 2021

Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression

A Phase 1 interventional study of Stereotactic Radiosurgery (SSRS) and Questionnaires in Metastatic Epidural Spinal Cord Compression, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn the feasibility of using a single session of radiation, known as spine stereotactic radiosurgery (SSRS), to treat metastatic epidural spinal cord compression.

Read the detailed description

Spinal cord compression is often treated with surgery followed by radiation in small doses every day for a number of days. When a patient cannot or will not have surgery, radiation is given daily. With increased accuracy and precision, higher doses of radiation can be given in a single session. Giving a higher dose in a single session may increase the chance that the tumor will stop growing into the spinal canal and will prevent spinal cord injury. This study will also help to identify the tolerance of the spinal cord to radiation in a single session.

Spine Stereotactic Radiosurgery:

You will lie in the mold that was made for you for 45-120 minutes while you receive your radiation treatment.

Follow-up Visits:

You will have follow-up visits at Months 3 (+/-2 weeks ), 6 (+/-4 weeks), 9 (+/-4 weeks), 12 (+/-8 weeks), 18 (+/-8 weeks), and 24 (+/-8 weeks) and then every 6 months after that. At each follow-up visit:

  • Your medical history will be recorded, including usage of steroids.
  • You will have a neurological exam.
  • You will complete the 3 questionnaires about health, symptoms you may be having, and about pain.
  • You will have an MRI of the spine.

If you are unable to return for follow-up clinic visits, you will be called and asked about your medical history, and you will complete the 3 questionnaires about your health, symptoms you may be having, and about pain. This call should take about 20 minutes.

Length of Study:

Your treatment will last 1 day. You will continue having follow-up visits or phone calls for as long as possible.

This is an investigational study. SSRS is FDA approved. The use of SSRS to treat metastatic epidural spinal cord compression is investigational.

Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.

02

Conditions studied

  • Metastatic Epidural Spinal Cord Compression

Keywords

  • Stereotactic Radiosurgery
  • SSRS
  • Radiation
  • Radiotherapy
  • Metastatic Epidural Spinal Cord Compression
  • MESCC
03

In context

Spinal Cord Compression

52 studies on the registry are indexed under Spinal Cord Compression; 19 are open to participants now.

This study's enrollment of 11 is below the median of 43 across 35 interventional studies indexed under Spinal Cord Compression.

Browse Spinal Cord Compression studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,047 studies on the registry; 578 are open to participants now.

Of its 612 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Greater than or equal to 18 years old
  2. Radiographically documented epidural compression on spine Magnetic resonance imaging (MRI) within 4 weeks of registration, defined radiographically, ranging from minimal canal compromise and thecal indentation to actual displacement of the spinal cord.
  3. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session
  4. Signed for irradiation
  5. Diagnosis of cancer including but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and unknown primary tumors
  6. Motor Strength >/= 4 out of 5 in extremity or extremities affected by the level of the spinal cord compression
  7. performance status (KPS) >/= 40
  8. Patients deemed to be inoperable due to patient refusal, by neurosurgical evaluation, or for any reason
  9. 1 prior course of spine radiotherapy to the current region of interest

Exclusion criteria

Exclusion Criteria:

  1. Prior irradiation of the site to be treated \</= 3 months prior to registration
  2. Inability to tolerate lying flat on treatment table for greater than 30 minutes.
  3. Patients unable to undergo MRI of the spine
  4. Patients who have previously received maximum cord tolerance of 45 Gy in 5 weeks conventional fractionation or similar biologically effective dose (BED) to the area of the spine to be treated. Below are the normalized BED at 2 Gy per fraction with alpha/beta=2 for spinal cord in commonly used fractionation schemes in previously irradiated patients. Conventional Radiotherapy (Normalized Biologically Effective Dose) 20 Gy in 5 fractions(30 Gy 2/2), 30 Gy in 10 fractions(37.5 Gy 2/2), 37.5 Gy in 15 fractions(42 Gy 2/2), 40 Gy in 20 fractions(40 Gy 2/2), 45 Gy in 25 fractions(43 Gy 2/2), 50 Gy in 25 fractions(50 Gy 2/2) following equation: nBED is calculated by dividing BED by (1 + d/a/b), where d is 2 Gy and for spinal cord late effect a/b is 2, and we describe the units as Gy 2/2 (i.e., Gy 2/2 = 2-Gy equivalent with a/b = 2)
  5. Patients who are pregnant.
  6. Patients who have cord compression from bone components or configuration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Stereotactic Radiosurgery (SSRS)

    Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.

    Procedure: Stereotactic Radiosurgery (SSRS) · Behavioral: Questionnaires

Interventions

  • ProcedureStereotactic Radiosurgery (SSRS)

    Target dose of 18 or 24 Gy to spine in single session of radiation.

    Also known as: Stereotactic Radiosurgery, SSRS, Radiation, Radiotherapy, Metastatic Epidural Spinal Cord Compression, MESCC

  • BehavioralQuestionnaires

    Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.

    Also known as: Surveys

06

What researchers measure

Primary outcomes

  1. Number of Occurrences of Paralysis Caused by Radiation Myelitis (RM)

    Maximum acceptable Dmax will be that in which there are fewer RM events than TP events prior to 12 months and less than 2 RM events.

    Time frame: Up to 12 months following radiation

07

Study locations

1 site
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2010 to primary completion in Oct 2021, 130 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2010
First posted
Dec 8, 2010
StartActual
Dec 3, 2010
Primary completionActual
Oct 15, 2021
CompletionActual
Oct 15, 2021
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01256554
Responsible party
Sponsor
First posted
Dec 8, 2010
Start date
Dec 3, 2010
Primary completion
Oct 15, 2021
Completion
Oct 15, 2021
Last update
Oct 25, 2021

Study contacts

Amol J. Ghia, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion